Drugs / MCLA-117
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03038230 | Apr 2016 → May 2021 | acute myeloid leukemia | Merus B.V. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCLA-117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03038230 ↗ |
| Modality | Monoclonal antibody | “a human bispecific IgG antibody” NCT03038230 ↗ |
| Target | CLEC12A | “targets CLEC12A” NCT03038230 ↗ |